About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

By: via GlobeNewswire

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of Gilead’s Livdelzi (seladelpar) and Ipsen’s Iqirvo (elafibranor). These additions to the therapeutic arsenal represent meaningful progress in disease management. However, new data from Spherix Global Insights’ Market Dynamix™: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis 2025 (US) reveal that pruritus—a persistent and often debilitating symptom—continues to pose a significant unmet need for many patients living with PBC.

Among the 104 US gastroenterologists surveyed in the study, there was near-universal agreement on the importance of addressing pruritus—one of the most burdensome and distressing symptoms associated with PBC. Respondents estimated that approximately half of their PBC patients suffer from moderate to severe pruritus, a manifestation that significantly impacts quality of life and remains challenging to manage. As one specialist poignantly noted, “Patients with cholestatic liver disease will go to the world’s end to escape from pruritus and the insomnia it causes.”

Most gastroenterologists surveyed also acknowledged a substantial unmet need for therapies specifically targeting PBC-associated pruritus. While Livdelzi has demonstrated a significant reduction in itch symptoms after six months of treatment, only about half of respondents reported that their patients on Livdelzi required no additional intervention for pruritus. The need for effective symptom control is even more pronounced among patients receiving Iqirvo, further highlighting the gap in adequate pruritus management and the continued demand for novel therapeutic approaches.

In June, GSK announced that the FDA had accepted the New Drug Application (NDA) for its ileal bile acid transporter (IBAT) inhibitor, linerixibat, for the treatment of cholestatic pruritus in patients with PBC. The PDUFA target action date is set for March 24, 2026. Awareness of the IBAT class is already high among gastroenterologists, and most report they are likely to incorporate linerixibat into their treatment armamentarium if approved. As one specialist expressed, “The results seem promising with a significant symptom reduction among moderate to severe pruritus. However, abdominal pain and diarrhea side effects are somewhat concerning and may limit real-world use.” Another echoed the sentiment, noting, “It significantly improved symptoms of pruritus along with quality of life, which can be a challenging and quite debilitating symptom to treat.”

If approved, linerixibat could represent a meaningful advancement for patients struggling with PBC-related pruritus—a symptom that continues to profoundly impair quality of life and remains inadequately addressed by current therapies. Spherix Global Insights will continue to closely track emerging developments across the PBC treatment landscape and pipeline through its Market Dynamix™: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis service.

Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

About Spherix Global Insights   

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.   

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.   

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.   

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.    

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com    

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. 


Jim Hickey, Gastroenterology Franchise Head
Spherix Global Insights
4848794284
james.hickey@spherixglobalinsights.com

More News

View More
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.